with haloperidol, Kane eta! (1988) found that 30% responded to clozapine. Both negative symptoms and positive symptoms improved. A retrospective study (Povlsen et a!, 1985) noted similar improvement. Claghorn et a! (1987) reported that clozapine was superior to chiorpromazine in a large group of patients who had experienced either extrapyramidal side-effects or tardive dyskinesia that had persisted during treatment with at least two neuroleptics. Meltzer et a! (1989) reported that over 60% of 51 treatment-resistant patients had a 20Â°lo decrease in total scores on psychiatric rating scales. Marked improvements in social function were also reported.
The pharmacological characteristics of clozapine set it apart from conventional neuroleptics. Its blockade of dopamine type-2 receptors is relatively weak and its blockade of dopamine type-i receptors strong compared with a conventional high-potency neuroleptic such as perphenazine (Farde eta!, 1989) . It has relatively high affinity for the dopamine type-4 receptor (Van Tol et a!, 1991) . It also acts as a serotonin receptor antagonist and a1 and a2 noradrenalin receptor antagonist (Richelson, 1984; Meltzer, 1989) . Furthermore, clozapine has potent anticholinergic effects (Richelson, 1980) .
There have been no previous neuropsychological investigations of the effects of clozapine on higher level cognitive functions in patients with schizo phrenia. One study (Ciassen & Laux, 1988) found that schizophrenic patients receiving clozapine did not differ from other groups of patients receiving haloperidol or flupenthixol on sensorimotor tasks. In the present study, we assessed schizophrenic patients' neuropsychological functioning and symptom status while on typical neuroleptics and while on clozapine, in order to examine whether the cognitive deficits reported in patients with schizophrenia are relatively fixed and enduring, or covary with psychopathology. This issue is critical in clarifying whether cognitive impairment is a primary manifestation of the illness or an epiphenomenon.
Method
Fifteenpatientswith psychosiscomprisedthe sample.Ten patientsfulfilledcriteriafor the diagnosisof undifferentiated schizophrenia, three for paranoid schizophrenia, one for psychosis not otherwise specified, and one for schizoaffective disorder.
In seven patients, diagnoses were made using the Structured Clinical Interview for DSM-III-R (Spitzer eta!, 1990 ). In the remaining patients, diagnoses were made according toDSMâ€"IIIâ€"R criteria (American Psychiatric Association, 1987) and based upon medical records, histories, and interviews. One patient had a pre-existing complex partialseizuredisorder,whilea secondhad an incompletely documented seizure disorder. All patients received trials of at least two typical neuroleptics, to which they failed to respond, before receiving clozapine. All patients had scores on the Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 1962) of 45 or greater and ratings on the Clinical Global Impression (CGI) scale (Guy, 1976) (four-subtests short form) (Wechsler, 1981; Silverstein, 1985) (b) Wechsler Memory Scale Form II (Lezak, 1976;  Wechsler& Stone, 1985) (c) Digit Symbol (Wechsler, 1981) Jastak & Wilkinson, 1985) .
Not all the patients were able to completeall the tests on both occasions (see Table 2 ). Performance was consideredimpaired if the score was more than 1 s.d. below published norms. Neither the examiner nor the patient were blind to drug condition.
Information about vocational functioning and living arrangementson each patient wasbasedon interviewswith Table 1 Medication of the sample 
Impaired performance.
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Table2
Mean (s.d.) scores for cognition, psychiatric symptoms and social status the patient and family. Living arrangements were rated 0 (group home), 1 (parental home), or 2 (independent living). Occupation was rated 0 (unemployed), 1 (job training), 2 (sheltered work), or 3 (college or part-or full-timecompetitiveemployment).
Psychiatric symptoms were rated on the BPRS. The total score and CGI, as well as factor scores for thought disturbance, anergia,and paranoia(hostility/suspiciousness), were calculated (Guy, 1976) . Raters were not blind to drug condition.
Resufts
There wereten men and fivewomenin the sample. Their meanagewas35years(range18â€"46 years).Themeanlength of illness was 12 years (range 3â€"21 years).
The BPRS scoresimprovedmarkedlyduring treatment with clozapine. Reductions in thought disturbance, anergia, and paranoia were significantby matched-pair f-tests, as was the reduction in total score. On average, symptom scoresdeclinedby 40%. CGI ratingsalso improvedsignifi cantly (Table 2) . Ten patients could be considered â€˜¿ responders' accordingto the criteria of Kaneeta! (1988) . No measureof cognitiveperformanceimprovedsignifi cantly on matched-pair f-tests in the clozapine phase of the study. One measure significantly worsened: visual reproduction (Table 2) . Performances on six measures were â€˜¿ impaired'in the typical-neuroleptic phase. Performances on seven measures were â€˜¿ impaired' during the clozapinephase ( (Torrey, 1988)) did not correlatesignificantlywith scoreson any cognitive measure (rho<0.37, P>0.20) in the typical-neuroleptic phase. Beforeadmission,and whiletakinga typicalneuroleptic, four patients had residedindependently,five had livedin supervised group homes, and six had lived with their parents. In the clozapine phase, one patient's living arrangement improved (from group home to independent living)and one patient's livingarrangement deteriorated (from parents' to group home). Thirteen patients' living arrangements did not change. Eleven patients were unemployed, one patient was a student, and three patients worked in competitive situations while taking a typical neuroleptic. In the clozapine phase, the job status of three patients improved (one from unemployed to competitive,two from unemployedto shelteredemploy ment), whiletwo worsened(from competitiveemployment to unemployed and from student to unemployed). Ten patients' vocational status did not change. Neither living arrangements nor vocational status improved significantly (Table 2) .
Discussion
The purpose of this study was to attempt to â€˜¿ dissect' psychiatric symptoms and cognition in schizophrenia. We used clozapine, not because it is an â€˜¿ atypical' neuroleptic with unusual psychopharmacological properties, but because it appeared likely to reduce symptoms markedly in patients in whom it is notoriously difficult toproduce change. Ifsymptoms and cognitive function were not dissociable, we would have expected improvements in symptoms to be reflected in improvements in cognitive function with clozapine treatment. However, we found improve ment in symptom status due to clozapine, but no change in cognitive functions. In fact, clozapine reduced psychiatric symptoms with great efficacy in psychotic patients. Key BPRS scores declined by 40@1o, and improvement was noted in thought disturbance, anergia, and para noia. Kay & Lindenmayer (1991) also found marked improvements in both positive and negative symp toms in patients receiving clozapine. Clinically, patients appeared much improved, and we informally observed that their affect was brighter, they were more cooperative, and they reported that they were less tense, worried, or preoccupied. Despite these fmdings, a wide range of cognitive functions remained impaired. Moreover, those patients whose psycho pathology improved most had no greater changes in cognitive function than did the patients whose symptoms improved the least. In 12 of the 13 cognitive tests, less than 50Â°lo of patients exhibited any improvement on clozapine, despite the possibility of practice effects on taking the tests a second time.
The findings suggest that cognitive dysfunction in schizophrenia is not simply due to â€˜¿ interference' caused by positive psychotic symptoms, or an epiphenomenon caused by lack of cooperation or motivation (Goldberg et a!, 1987) , but is to a considerable degree independent of psychopathology.
The actual pattern of abnormalities (i.e. on the Wisconsin Card Sorting Test, Wechsler Memory Scale's logical memory, Category Test, and Trails B tests of psychomotor speed) is typical of patients with schizophrenia (Goldberg eta!, 1990) , and may reflect frontotemporal dysfunction (Kolb & Whishaw, 1983;  Taylor & Abrams, 1984).
In light of the dramatic improvement in symp toms, an argument might be advanced that neuro psychological dysfunction is an interesting, but irrelevant clinical aspect of schizophrenia. We believe, however, that the data are more consistent with the conclusion that neuropsychological deficits are enduring and fundamental manifestations of the illness that account for much of the chronic social and vocational disability. Elsewhere, we have reported that cognitive measures are related to global functioning (Brier eta!, 1991; Goldberg eta!, 1992 of the 15 patients had been taking clozapine for more than six months by the time of the second assessment, any improvements in social and vocational function ing would have been detected (Meltzer, 1989) . It might be argued that patients were not symptom-free and so symptoms might still have exerted an effect. However, symptom scores were low, at a mean of 1.7 per item on the BPRS. A more detailed analysis of social behaviour and social-role performance would still be valuable in future studies. Our findings are consistent with studies of the effects of typical neuroleptics on cognition. These medications do not generally have a great effect on complex cognitive functions in schizophrenia (Heaton & Crowley, 1981; Medalia et a!, 1988; Spohn & Strauss, 1989; Cassens et a!, 1990; Cleghorn et a!, 1990; King, 1990 )and other neuropsychiatric disorders (Bornstein & Yang, 1991) , although they markedly reduce such positive symptoms as thought disorder Clozapine had an adverse effect on a measure of visual memory. Clozapine is the most potent anticholinergic oftheavailable neuroleptics andthe cholinergic system is known to play an important role inmemory (Drachman& Leavitt, 1974; Coyleeta!, 1983) . In fact, clozapine is only 17 times less potent than the anticholinergic agent benztropine, but is administered in dosages that are typically 100 times greater (Snyder et a!, 1974; Snyder & Yamamura, 1977) . A number of investigators have observed a relationship between impaired memory and the anti cholinergic effects of medications (i.e., benztropine, trihexyphenidyl, mesoridazine) in schizophrenia (Tune eta!, 1982; Perlick et a!, 1986). Clozapine may also impair cognition in normal subjects as a result of its anticholinergic activity (Saletu et a!, 1987) .
We recognise that our sample was small. How ever, we were easily able to detect changes in psychiatric symptoms. Moreover, although matched pair within-group designs offer greater power than do independent between-group designs (Louis eta!, 1984) ,the sizesof the differences on the cognitive tests between the drug conditions were exceedingly small. Therefore, it would be difficult to conclude that an effect was present, but the statistical power of the study was insufficient. Another criticism that might be raised is the use of the adjunctive psychotropic medications, which might somehow have biased the results. How ever, approximately equal numbers of patients received them in the two phases of the study, thereby grossly controlling for the possibility of anartefactual fmding.
Furthermore, changes in cognitive scores did not differ significantly between the patients receiving and not receiving an adjunctive psychotropic medication. In general, patients received less adjunctive medication during theclozapine phase than the typical-neuroleptic phase. This might be thought to confer some advantage to cognition in the clozapine phase, especially in light of symptomatic improvement. That it did not could reflect clozapine's high intrinsic anticholinergic potency and its adverse effect on mnemonic func tions in particular. While an argument might then be advanced that anticholinergic effects mask overall cognitive improvement, two factors would militate against it. Firstly, non-mnemonic cognitive factors that are relatively insensitive to anticholinergics also failed to improve. Secondly, patients whose symptoms improve with typical high-potency neuroleptics that have low intrinsic anticholinergic potencies also do not have significant cognitive gains (Gold & Hurt, 1990) . The psychiatric ratings were not done blind. However, it is unlikely that this could have biased the composition of the two subgroups of patients who improved most and least. As noted above, the changes in cognitive scores of these two groups did not differ. It should also be noted that most patients were tested on clozapine while they were out-patients, and that testing in the clozapine phase always followed that of the typical-neuroleptic phase. Both of these facets of the design might have inflated performance in the clozapine phase. That they did not strengthens the interpretation of the results. The battery of tests was intentionally limited, to reduce type-I error, and restricted to tests on which patients with schizophrenia are often impaired.
We do not wish to leave the impression that an improvement in psychotic symptoms in patients with schizophrenia is unimportant: this can help patients' sense of well-being and dramatically reduce personal, as well as family, tension. Reduction in hallucinations, delusions, and thought disorder, by minimising inter ference with behaviour and goal-directed thoughts, demands on attention, and problems in communi cation, could result in gains in social roles and vocational status. However, the results from the present study suggest that other variables, particularly those of a cognitive nature, may also be associated with long-term morbidity. The lack of change in living arrangement and vocational status is probably meaningful, given the length of time patients had been on clozapine (over 15 months) and that most patients had the opportunity to acquire social skills before the onset of illness (the mean age of which was 23 years).
In summary, clozapine was impressive in reducing symptoms in patients with chronic schizophrenia, but it did not have a marked effect on cognitive impairments, which appear to be intrinsic features of the disease. Since the social and vocational adjustment of the patients remained marginal, cognitive impairment may have been rate-limiting in the rehabilitation of this sample of patients. performance of schizophrenic inpatients treated with haloperidol, flupenthixol, or clozapine. Pharmacopsychiatry, 21, 295â€"297.
